Illustration: Gabriella Turrisi/Axios
Triton-backed Clinigen is paying a high-teens EBITDA multiple for biotech consultancy SSI Strategy, two sources familiar with the situation say.
Why it matters: PE-backed pharma services businesses continue to command rich valuations.